Deprescribing

When Should You Deprescribe Long-Term Proton Pump Inhibitors?

Quick answer

Many patients are on long-term PPIs without a persisting indication. After 8 weeks of therapy, reassess: if reflux resolved and no Barrett esophagus, bleeding ulcer history, Zollinger-Ellison, or ongoing NSAID/antiplatelet use, step down to H2 blocker or on-demand dosing. COMPASS reassures that long-term pantoprazole is safe for most; risks of pneumonia, fracture, and C. difficile are small but real and justify periodic review.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

COMPASS PPI safety substudy (2019)

PMID 31152740

17,598 on pantoprazole vs placebo, 3-year RCT

No significant increase in pneumonia, fractures, CKD, dementia, or cancer. Small increase in enteric infections (HR 1.33).

Targownik et al. fracture cohort (2008)

PMID 18695179

15,792 osteoporotic fractures matched to 47,289 controls

PPI use ≥5 years associated with hip fracture (OR 1.62, 95% CI 1.02–2.58). Effect modest and dose-dependent.

Inadomi et al. step-down strategy (2001)

PMID 14499769

73 primary-care patients on long-term PPI

58% successfully stepped down to H2 blocker or OTC at 1-year follow-up. Structured approach doubles success.

Practical decision algorithm

IfThen
Uncomplicated GERD, asymptomatic on PPI ≥8 weeksStep down: halve dose for 2 weeks, then switch to H2 blocker or on-demand. Lifestyle modifications.
Barrett esophagusContinue PPI indefinitely — reduces dysplasia progression.
History of bleeding peptic ulcer, ongoing NSAID/antiplateletContinue PPI as prophylaxis.
Rebound acid hypersecretion on attempted taperTaper over 4 weeks; bridge with H2 blocker; use alginate/antacid PRN.
Erosive esophagitis LA grade C/DContinue PPI; maintenance therapy indicated.

Guideline position

ACG 2022 GERD guideline: step down after symptom resolution in uncomplicated GERD. Choosing Wisely (AGA): avoid continuous PPI without clear indication. Canadian deprescribing guideline: reassess after 4–8 weeks.

Contraindications and cautions

  • Barrett esophagus — do not deprescribe
  • Active bleeding ulcer within 12 months
  • Zollinger-Ellison syndrome
  • Chronic NSAID or dual antiplatelet therapy — continue as gastroprotection
  • Severe erosive esophagitis (LA C/D) — maintenance

Frequently asked questions

Are the kidney and dementia signals real?
Observational associations are confounded by indication; randomized data (COMPASS) show no significant signal over 3 years. Do not refuse or stop PPI solely based on these concerns when a clear indication exists.
What about rebound hypersecretion?
Real — 40% of long-term PPI users have rebound symptoms on abrupt stop. Taper over 2–4 weeks, bridge with H2 blocker or famotidine.
Is famotidine a safe long-term alternative?
Yes. Fewer drug-drug interactions and less hypomagnesemia. Less potent acid suppression — suitable for mild-moderate reflux.
How does PPI interact with clopidogrel?
Omeprazole and esomeprazole inhibit CYP2C19, blunting clopidogrel activation. Prefer pantoprazole or rabeprazole. COGENT trial showed no clinical events, but pharmacologic interaction is real.
What about vonoprazan?
Potassium-competitive acid blocker — faster onset, more potent acid suppression. Approved for erosive esophagitis and H. pylori. Reasonable in PPI-refractory GERD; safety data still accumulating.

Further reading

Clinical Reasoning

Polypharmacy in Elderly Patients: An Evidence-Based Deprescribing Framework

Methodology

Iron Deficiency Anemia: IV Iron Formulations and Indications

Evidence-Based Medicine

Drug-Nutrient Interactions Physicians Miss: A Cross-System Review

Back to all decision points